Abstract
Post-transcriptional regulation plays a leading role in gene regulation and RNA binding proteins (RBPs) are the most important posttranscriptional regulatory protein. RBPs had been found to be abnormally expressed in a variety of tumors and is closely related to its occurrence and progression. However, the exact mechanism of RBPs in bladder cancer (BC) is unknown. We downloaded transcriptomic data of BC from the Cancer Genome Atlas (TCGA) database and used bioinformatics techniques for subsequent analysis. A total of 116 differentially expressed RBPs were selected, among which 61 were up-regulated and 55 were down-regulated. We then identified 12 prognostic RBPs including CTIF, CTU1, DARS2, ENOX1, IGF2BP2, LIN28A, MTG1, NOVA1, PPARGC1B, RBMS3, TDRD1, and ZNF106, and constructed a prognostic risk score model. Based on this model we found that patients in the high-risk group had poorer overall survival (P < 0.001), and the area under the receiver operator characteristic curve for this model was 0.677 for 1 year, 0.697 for 3 years, and 0.709 for 5 years. Next, we drew a nomogram based on the risk score and other clinical variables, which showed better predictive performance. Our findings contribute to a better understanding of the pathogenesis, progression and metastasis of BC. The model of these 12 genes has good predictive value and may have good prospects for improving clinical treatment regimens and patient prognosis.
Highlights
Bladder cancer (BC) is one of the most common malignant tumors worldwide and the most common malignant tumor in the urinary system, with more than 400,000 new cases diagnosed and 160,000 deaths annually (Torre et al, 2015; Antoni et al, 2017)
Post-transcriptional gene regulation is crucial for maintaining cell function, and RNA binding proteins (RBPs) are the most important posttranscriptional regulatory factors
RBPs participate in most steps of post-transcriptional regulation, determine the fate and function of each transcript in cells, and ensure cell homeostasis (Pereira et al, 2017)
Summary
Bladder cancer (BC) is one of the most common malignant tumors worldwide and the most common malignant tumor in the urinary system, with more than 400,000 new cases diagnosed and 160,000 deaths annually (Torre et al, 2015; Antoni et al, 2017). BC is a heterogeneous tumor with two subtypes: non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC). NMIBC rarely progresses, but half of patients develop. RNA Binding Proteins in BC tumor recurrence within 5 years, and 20–30% of NMIBC patients progress to MIBC (Chamie et al, 2013). MIBC progresses frequently, and the 5-year survival rate is as low as 8.1% (Abdollah et al, 2013). Multiple studies have revealed potential biomarkers and therapeutic targets for BC (Cancer Genome Atlas Research Network, 2014; Knowles and Hurst, 2015; Pietzak et al, 2017), and significant advances have been made in surgical techniques and adjuvant chemotherapy, the mortality rate for advanced BC remains high, and the pathogenesis and progression of BC remain unclear (Siegel et al, 2015). Further understanding of the molecular mechanisms of BC occurrence, progression, and invasion may improve the early detection and diagnosis of BC
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
